ASweetLife Team, Author at ASweetLife

A Day in the Life of Diabetes

Too many Americans think of diabetes as a minor hindrance rather than a life-changing disease. But the American Diabetes Association wants to show America what a day in the life of diabetes is really like. This year’s campaign for American Diabetes Month, which kicked off on October 1 calls for people to share a personal image representing what A Day in the Life of Diabetes means to them via its Facebook page.

Hypoglycemia Common Among Type 2 Diabetes Patients Treated with Insulin

According to the GAPP2™ (Global Attitudes of Patients and Physicians) survey, funded by Novo Nordisk and presented today at the Annual Meeting of the European Association for the Study of Diabetes (EASD), four out of five (80%) people with type 2 diabetes have experienced self-treated hypoglycemia...

Lantus Insulin More Effective in Achieving Long Term Blood Sugar Control in Type 2 Diabetes Patients

New results presented by Sanofi at European Association for the Study of Diabetes (EASD) 48th Annual Meeting showed treatment with Lantus (insulin…

Novo Nordisk’s New Ultra-Long-Acting Insulin Degludec Shows Lower Rate of Hypoglycemia

Data from two new studies shows patients with type 2 diabetes starting insulin therapy had a 43% lower rate of night-time hypoglycemia when using degludec, Novo Nordisk’s ultra-long-acting insulin, compared with those using insulin glargine (Lantus).

Type 1 Diabetes TrialNet Prevention Study Open to Younger Children

Incidence of type 1 diabetes is increasing and the disease is presenting at earlier ages. Each year, in the U.S. alone, approximately 15,000 children and adolescents are diagnosed with type 1 diabetes. It is one of the most common chronic diseases in school-aged children.

Novo Nordisk’s Ultra-Long Acting Insulin, Tresiba, Approved in Japan

The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk's ultra-long acting insulin, insulin degludec, for treatment of diabetes. Insulin degludec, marketed globally under the name Tresiba, is a new generation of once-daily basal insulin, which has been discovered and developed by Novo Nordisk.

Biodel Receives NIH Grant to Develop Glucagon Formulations For Artificial Pancreas

The Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel Inc. a grant for the development of novel and stable glucagon formulations for use in an artificial pancreas, also known as a closed loop pump system. The SBIR program is a highly competitive program that encourages domestic small businesses to engage in Federal Research/Research and Development that has the potential for commercialization.

Raising Funds for the Schuhmacher Family

Meri Schuhmacher writes the blog Our Diabetic Life. Her husband Ryan passed away earlier this month after a battle with cancer. Meri, a beloved member of the diabetes community, is now left to care for her fours sons alone, and three of her sons have type 1 diabetes.

Boehringer and Lilly Introduce Online Program for Adults with Type 2 Diabetes

Boehringer Ingelheim and Eli Lilly and Company have announced the availability of My Well Planner, a new online program offering customized educational content to help adults with type 2 diabetes make simple lifestyle changes to improve their health. My Well Planner is designed to address the emotional barriers people with type 2 diabetes face every day.

Zealand Pharma Begins Phase 1 Study of Type 2 Diabetes Drug

Zealand Pharma, a Danish biotechnology company dedicated to the discovery and development of innovative peptide drugs, announced the start of the first Phase I clinical study of ZP2929. ZP2929 is a dual acting glucagon/GLP-1 peptide agonists, invented by Zealand Pharma and with global rights out-licensed to Boehringer Ingelheim as part of a global license and research ...